It’s personal

Improving the lives of patients is a personal matter for each and every member of our team at Protagen. You’ll see this in the passion we apply to the discovery, identification, and validation of novel biomarker panels for better diagnostic (Dx) and companion diagnostic (CDx) tests. It is demonstrated by the commitment and expertise we bring to our partnerships when working on clinical development programs. Our dedication to advancing diagnostics for personalized medicine is evident in everything we do.

Diagnostics Differentiated

We are adding a new dimension to the world of diagnostics. Our SeroTag biomarker development engine delivers unique biomarker signatures. The disease-specific signatures that we identify, often based on novel markers, are the basis for new diagnostic strategies that will improve the differentiation and stratification of patients. The result is a new medical scenario in which disease states are recognized earlier, and medical care can be more specifically and effectively provided.

Learn more


Protagen AG have been nominated as one of three finalists in the 'Best Personalized Medicine Advance or Application' category of the prestigious Clinical and Research Excellence (CARE) awards

Protagen AG have been nominated based on the NavigAID Systemic Lupus Erythematosus (SLE) array that was developed using the proprietary Protagen SeroTag® technology. NavigAID SLE measures autoantibodies associated specifically with SLE and also identifies subsets of autoantibodies associated with particular SLE disease states and pathologies. This is the first time it has been possible to differentiate between different SLE patient subgroups and currently this technology is being applied to the development of an SLE companion diagnostic with a global pharmaceutical partner.

Novel route to serum based Prostate Cancer Diagnostics

Protagen AG, technology leader in the development of novel molecular diagnostic and companion diagnostic tests for autoimmune diseases and oncological indications, announced today the identification of novel protein biomarkers in prostate cancer, which are potential drug targets supporting novel strategies in precision medicine.

Protagen AG joins RA-MAP Consortium to support Identification of Predictors of Remission in Rheumatoid Arthritis (RA)

Protagen AG, a company concerned with the development of advanced diagnostic tools to address some of the most severe autoimmune diseases, has today announced that it will join the RA-MAP Consortium. The overarching goal of the Consortium is to identify the key predictors of clinical response and remission in RA patients, and to identify those individuals at high risk of developing Rheumatoid Arthritis (RA).